Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with high-dose chemotherapy in advanced ovarian cancer
NCT00583622Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2007
- Primary completion
- Jan 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in ovarian cancer, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Event-Free Rate at 6 months. Started Dec 2007; status: terminated.
02
Drugs
bevacizumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00583622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00583622.